薷蒿达湿方治疗流行性感冒湿遏卫气证随机对照研究OA

Objective To evaluate the clinical efficacy and safety of the Ruhao Dashi Formula(RHDSF)in treating influenza with dampness-obstructing defense-qi syndrome.Methods A randomized controlled trial was conducted,enrolling 300 patients diagnosed with influenza presenting dampness-obstructing defense-qi syndrome.Participants were assigned to the RHDSF group(120 cases),the Huoxiang Zhengqi Shui(HXZQS)group(60 cases),and the Western medicine control group(120 cases)according to ratio of 1∶0.5∶1.The Western medicine control group received oseltamivir capsules alone,while the RHDSF and HXZQS groups received their respective herbal medications in addition to the Western medicine.Assessments were conducted on the third day of treatment,which included the influenza cure rate,total effective rate,Chinese medicine(CM)syndrome score,markedly effective rate of CM syndromes,and total effective rate of CM syndromes,time to fever relief,the number of cases with complete fever resolution,relief rates of influenza symptoms,and incidence of adverse reactions.Results On the third day of treatment,the RHDSF group exhibited a significantly higher influenza cure rate,total effective rate,markedly effective rate of CM syndromes,and total effective rate of CM syndromes compared with the Western medicine control group(P＜0.01).Additionally,the number of cases with complete resolution of fever was greater(P＜0.01).Furthermore,the CM syndrome score and time to fever relief were significantly reduced(P＜0.05).The relief rates for influenza symptoms,including headache,fever,muscle or joint pain,fatigue,nasal congestion,sore throat,and cough,were also higher in this group(P＜0.05).Compared with the HXZQS group,influenza cure rates,effective rates of CM syndromes,and relief rates for nasal congestion and cough increased in the RHDSF group(P＜0.05).The adverse reaction rate in the RHDSF group was 4.17％,significantly lower than the 16.67％observed in the HXZQS group(x2=8.182,P＜0.01).Adverse reactions were predominantly mild,including nausea or diarrhea,with no serious adverse events reported.Conclusions RHDSF significantly improves both disease efficacy and CM syndrome efficacy in treating influenza with dampness-obstructing defense-qi syndrome.It effectively alleviates fever and other influenza symptoms with a favorable safety profile.